Non-comparative Evaluation of Facial Expressions Following Lower Face Correction Using Emervel Classic and Emervel Deep

Exclusion Criteria

• •1. Subject who presents with a severity of wrinkles or folds that require other treatments, e.g. laser treatment, chemical peeling, to achieve optimal correction
• •2. Previous facial surgery, including aesthetic facial surgical therapy, liposuction or tattoo, in the treatment area
• •3. Previous tissue augmenting therapy or contouring with permanent filler-type injectable product
• •4. Previous tissue augmenting therapy with non-permanent filler or fat-injection in the facial area to be treated, within twelve (12) months before treatment
• •5. Previous tissue revitalisation treatment with neurotoxin below the zygomatic arch, within six (6) months before treatment
• •6. Previous tissue revitalisation treatment with laser or light, mesotherapy, chemical peeling or dermabrasion below the zygomatic arch within six (6) months before treatment
• •7. Subject who presents with severe midface volume loss
• •8. Subject has a beard or facial hair that, in the investigator's opinion, would interfere with the study injections and/or study assessments
• •9. Woman who plans to become pregnant during the study
• •10. Woman who is pregnant or breast feeding
• •11. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel
• •12. Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or other amide-type anaesthetics
• •13. Known/previous allergy or hypersensitivity to gram-positive bacterial proteins
• •14. History of severe or multiple allergies manifested by anaphylaxis
• •15. History of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation within two (2) weeks before treatment
• •16. Treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic or topical (facial) corticosteroids (inhaled corticoids are allowed) within three (3) months before study treatment
• •17. Any medical condition or treatment that, in the opinion of the treating investigator, would make the subject unsuitable for inclusion
• •18. Study site personnel, close relatives of the study site personnel (e.g. parents, children, siblings, or spouse), employees, or close relatives of employees at the Sponsor company
• •19. Participation in any clinical study within thirty (30) days before treatment